SCHEMBL8031003

SCHEMBL8031003

COc1cccc(-n2cc(C)nc2-c2ccccc2C)c1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 4/20 0.41
ATP4B P51164 4/20 0.41
PDE2A O00408 1/20 0.41
PDE6D O43924 1/20 0.41
PDE6A P16499 1/20 0.41
PDE6G P18545 1/20 0.41
PDE4A P27815 1/20 0.41
PDE6B P35913 1/20 0.41
PDE6C P51160 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
PDE6H Q13956 1/20 0.41
PDE10A Q9Y233 1/20 0.41
HSP90AA1 P07900 1/20 0.40
EPHB4 P54760 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HTR7 P34969 1/20 0.37
ALDH1A1 P00352 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8031000 0.81 ATP4A (0.38) ATP4AATP4BPDE2APDE6DPDE6A
SCHEMBL969679 0.81 RXFP1 (0.41) ATP4AATP4BPDE2APDE6DPDE6A
SCHEMBL12920154 0.78 HSD17B10 (0.48) HSP90AA1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL3324079 0.69 PDE2A (0.39) PDE2APDE6DPDE6APDE6GPDE6B
SCHEMBL26186287 0.67 CD44 (0.45) HSP90AA1MEN1KMT2AALDH1A1KDM4E
SCHEMBL27374278 0.67 KDM4E (0.50) PDE2APDE10AHSP90AA1KMT2AALDH1A1
SCHEMBL29486564 0.66 CD44 (0.52) ALDH1A1KDM4EMAPTTSHRSMN1; SMN2
SCHEMBL288824 0.66 CD44 (0.52) ALDH1A1KDM4EMAPTTSHRSMN1; SMN2
SCHEMBL12104260 0.65 TOP1 (0.48) PDE2APDE6DPDE6APDE6GPDE4A
SCHEMBL31607623 0.65 ALDH1A1 (0.52) HSP90AA1MEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
US-7875618-B2 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) WYETH (US) 2011-01-25 US disclosed
WO-2009070584-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 WYETH (US) 2009-06-04 WO disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 ELBION GMBH (DE) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143367-A1 ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 PDE12, PDE5A, PDE10A ATP4A 3103/4885ATP4B 3500/4885PDE2A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.